Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.7 |
mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | 0.077 | 0.7 |